Diabetes raises blood potassium through several overlapping mechanisms, not just one. Insulin normally drives potassium from the bloodstream into cells, so when insulin is deficient or ineffective, potassium accumulates in the blood. On top of that, diabetes gradually damages the kidneys’ ability to excrete potassium and disrupts the hormonal signals that regulate potassium disposal. The medications many people with diabetes take to protect their kidneys and heart can make the problem worse, creating a situation where hyperkalemia becomes one of the most common and underappreciated electrolyte disturbances in diabetes care.
Insulin Keeps Potassium Inside Your Cells
Most of the potassium in your body sits inside cells, not floating in the bloodstream. The pump responsible for maintaining that arrangement is an enzyme embedded in cell membranes called Na+/K+-ATPase. It continuously shuttles sodium out and potassium in, keeping the concentration gradient steep enough for nerves and muscles to function properly. Insulin is one of the key signals that activates this pump. When insulin is circulating normally, the pump works efficiently to pull potassium out of the blood and tuck it into muscle and liver cells.
In type 1 diabetes, the body produces little or no insulin. In type 2 diabetes, cells respond poorly to insulin, and over time the pancreas may not produce enough. Either way, the pump loses its signal. Research has shown that insulin upregulates Na+/K+-ATPase and restores its transport efficiency, so without adequate insulin the pump’s activity drops and potassium drifts outward into the bloodstream.1Spandidos Publications (Exp Ther Med). Regulatory effect of insulin on the structure, function and metabolism of Na(+)/K(+)-ATPase (Review) This shift between the inside and outside of cells is called transcellular redistribution, and it can raise serum potassium even when the total amount of potassium in the body hasn’t changed. It’s the quickest route from insulin problems to a high potassium reading on a blood test.
Why the Kidneys Stop Clearing Potassium
Under normal circumstances, your kidneys handle the lion’s share of potassium disposal. When blood potassium rises, a hormone called aldosterone signals the kidney tubules to excrete more of it in the urine. The chain of events that produces aldosterone starts with renin, an enzyme released by specialized kidney cells, which eventually triggers aldosterone release from the adrenal glands.
Diabetes can break this chain at multiple points. Many people with longstanding diabetes develop a condition called hyporeninemic hypoaldosteronism, a state where the kidneys release too little renin and, as a result, aldosterone levels stay low. Without enough aldosterone, the kidney tubules don’t get the signal to dump potassium into the urine, and levels creep up. This hormonal deficiency is the hallmark of what clinicians call type IV renal tubular acidosis, which a recent review identified as an important and treatable cause of generally mild hyperkalemia in people with diabetes.2Frontiers. Underestimated reason of hyperkalemia in diabetic patients: type IV renal tubular acidosis- mini review
The result is a chronic, low-grade potassium elevation that may not set off alarms on a single lab draw but accumulates risk over time. Because type IV renal tubular acidosis also causes a mild metabolic acidosis, the two problems reinforce each other: acidosis pushes even more potassium out of cells and into the blood, while the kidney’s impaired excretion fails to compensate.
Autonomic Neuropathy Adds Another Layer
Diabetes is well known for damaging nerves, and the autonomic nervous system is no exception. Autonomic neuropathy affects involuntary processes like heart rate, blood pressure, and digestion. Less obviously, it also influences renin release. The sympathetic nerves that run to the kidney’s juxtaglomerular cells play a direct role in stimulating renin secretion, especially when you change posture or become dehydrated.
Classic research showed that people with diabetes and autonomic neuropathy severe enough to cause postural hypotension had essentially no increase in plasma renin activity when they stood up, whereas those without that degree of neuropathy responded normally.3PubMed. Plasma renin activity in diabetic autonomic neuropathy The investigators noted that the nerve damage alone didn’t fully explain the blunted renin response and suggested that structural kidney damage involving the renin-producing cells could also be involved. Regardless of the exact mix, the end result is the same: less renin means less aldosterone, which means less potassium in the urine and more in the blood.
The Paradox of Diabetic Ketoacidosis
Diabetic ketoacidosis, or DKA, creates one of the most confusing potassium scenarios in medicine. A person in DKA is typically severely depleted of total body potassium because of fluid losses, vomiting, and increased urinary excretion from the osmotic diuresis of very high blood sugar. Yet the serum potassium reading on their lab work is often normal or even high. One study noted that serum potassium is normal or high in the majority of patients with DKA despite significant total body potassium deficits.4Diabetes & Metabolism Journal. Metabolic Factors Influencing Serum Potassium Levels in Diabetic Ketoacidosis
Several forces conspire to produce this illusion. The near-total absence of insulin means the Na+/K+-ATPase pump is barely working, so potassium leaks out of cells. The severe acidosis from accumulated ketoacids forces additional potassium out of cells in exchange for hydrogen ions moving in. And the concentrated, dehydrated blood makes the potassium that remains appear more concentrated than it really is. Once treatment begins and insulin is given, potassium rushes back into cells and the serum level can plummet dangerously. This is why potassium monitoring during DKA treatment is so critical: the high number on the initial lab test masks an underlying deficit that will reveal itself as insulin therapy takes hold.
Medications That Compound the Risk
If diabetes alone weren’t enough, the drugs prescribed to manage it and its complications often push potassium higher. People with diabetes frequently have high blood pressure, heart failure, or diabetic kidney disease, all of which are commonly treated with drugs that interfere with the renin-angiotensin-aldosterone system (RAAS). ACE inhibitors and angiotensin receptor blockers are cornerstones of kidney protection, but they work precisely by suppressing the system that helps the kidney excrete potassium. Adding a mineralocorticoid receptor antagonist like spironolactone on top further blocks aldosterone’s effect in the kidney tubule.
A network meta-analysis of people with diabetic kidney disease found that adding mineralocorticoid receptor antagonists to an ACE inhibitor or ARB sharply increased hyperkalemia compared with placebo, with spironolactone in combination with an ACE inhibitor or ARB producing even higher odds of hyperkalemia than dual RAAS blockade with two different drug classes.5PubMed Central. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis The same review noted that polypharmacy is extremely common in people with diabetes because of their burden of co-existing conditions, and each additional drug that touches the RAAS pathway stacks the hyperkalemia risk further.2Frontiers. Underestimated reason of hyperkalemia in diabetic patients: type IV renal tubular acidosis- mini review
This creates a clinical tension: the drugs most proven to slow diabetic kidney disease and reduce cardiovascular death are the same drugs most likely to cause hyperkalemia. Clinicians sometimes have to reduce the dose of these protective medications or stop them entirely because potassium levels get too high, which means the patient loses out on their benefits.
SGLT2 Inhibitors Buck the Trend
Amid all these potassium-raising forces, one newer class of diabetes drugs appears to push in the opposite direction. SGLT2 inhibitors, which lower blood sugar by blocking glucose reabsorption in the kidney, have consistently shown a modest potassium-lowering effect. A large meta-analysis of individual participant data from randomized controlled trials found that SGLT2 inhibitors reduced serious hyperkalemia by about 16%, and the benefit held across subgroups defined by kidney function, heart failure history, and use of RAAS inhibitors.6PubMed. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials A separate meta-analysis found that SGLT2 inhibitors reduced the odds of hyperkalemia events by roughly 28% compared with placebo, although the actual change in serum potassium concentration was tiny.7PubMed. Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysis
A pooled analysis of the SGLT2 inhibitor dapagliflozin found no clinically meaningful shifts in potassium, even in people with moderate kidney impairment or those already taking ACE inhibitors, ARBs, or potassium-sparing diuretics.8PubMed Central. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis The mechanism isn’t entirely settled, but the increased urine flow from SGLT2 inhibition likely enhances potassium delivery to the distal tubule, where it can be secreted. Whatever the explanation, SGLT2 inhibitors are unusual among diabetes medications in that they appear to help rather than worsen the hyperkalemia problem.
Newer Options for Keeping Protective Drugs on Board
Because hyperkalemia frequently forces clinicians to reduce or stop RAAS inhibitors, researchers have developed potassium binders that can be taken alongside those drugs to keep potassium in range. Two newer binders, patiromer and sodium zirconium cyclosilicate, work in the gut by trapping potassium and preventing its absorption. In systematic review data, over 90% of patients treated with these agents were able to maintain, initiate, or increase their RAAS inhibitor doses during the maintenance phases of clinical studies.9PubMed Central. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia
A recent trial in people with diabetic kidney disease specifically tested sodium zirconium cyclosilicate as an enabler for ACE inhibitor and ARB therapy. Over 12 weeks, roughly 56% of patients receiving the potassium binder alongside their RAAS inhibitor were able to increase their RAAS inhibitor dose, compared with about 28% in the group without the binder. By 24 weeks, albumin-to-creatinine ratio, a marker of kidney damage, had dropped in the binder group while it rose in the control group.10PubMed. Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs/ARBs use in the treatment of patients with diabetic kidney disease The practical implication is significant: these binders let patients keep taking the drugs that protect their kidneys and hearts, rather than sacrificing long-term organ protection because of a potassium number on a lab test.
Finerenone Versus Traditional Mineralocorticoid Blockers
Spironolactone and eplerenone, the older mineralocorticoid receptor antagonists, are effective at slowing kidney disease progression but carry a substantial hyperkalemia burden, as the network meta-analysis data described earlier illustrate. Finerenone is a newer, nonsteroidal mineralocorticoid receptor antagonist designed to retain the kidney and heart benefits while reducing the hyperkalemia risk. Clinical trials have shown that finerenone significantly reduces the risk of cardiorenal disease progression compared with placebo and has a lower incidence of hyperkalemia than the older steroidal agents.11American Journal of Health-System Pharmacy. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes
A target trial emulation comparing finerenone directly with spironolactone in people with chronic kidney disease and type 2 diabetes found that finerenone was associated with lower rates of major cardiovascular events, major kidney events, and all-cause mortality. The hyperkalemia rate was about 17% in the finerenone group versus roughly 26% with spironolactone.12PubMed Central. Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation Finerenone doesn’t eliminate the risk, but it narrows it enough that more patients can stay on therapy at effective doses.
When the Lab Says High Potassium but the Body Disagrees
Not every elevated potassium result in a person with diabetes reflects a genuine problem. Pseudohyperkalemia is a lab artifact where potassium measured in the blood sample is higher than the true level circulating in the patient’s body. It happens most often when blood cells break apart during or after the blood draw, releasing their intracellular potassium into the sample. Factors like a difficult draw, a tight tourniquet left on too long, vigorous fist clenching, or delayed processing of the sample can all cause it.
A case series illustrated the issue with a 44-year-old man who had diabetes, hypertension, and stage III chronic kidney disease. His potassium readings across multiple blood draws ranged from 5.4 to 6.5 mmol/L, yet his electrocardiogram showed no signs of hyperkalemia and his other chemistries were unremarkable for that degree of elevation.13The American Journal of Medicine. Review Pseudohyperkalemia: Three Cases and a Review of Literature In cases like this, the clinical picture doesn’t match the number, and repeating the blood draw with careful technique or using a plasma (rather than serum) sample can reveal the discrepancy. The danger of pseudohyperkalemia is overtreatment: a patient might receive aggressive potassium-lowering therapy or have beneficial medications withheld based on a number that was never real.
Dietary Potassium and the Gut’s Backup Role
People with diabetes and declining kidney function are often told to restrict potassium in their diet. The logic seems straightforward: if your kidneys can’t clear potassium efficiently, eat less of it. But the relationship between dietary potassium and serum levels is more complicated than that simple instruction suggests. Many potassium-rich foods, especially fruits, vegetables, and legumes, carry substantial health benefits that may outweigh the theoretical risk of mild potassium elevation.
As kidney function worsens, the gut appears to pick up some of the slack. In healthy adults, only about 10% of potassium intake is excreted through the colon. In people with kidney failure, fecal potassium excretion may be roughly three-fold higher, suggesting a compensatory adaptation.14Kidney Medicine. Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet The colon’s role in potassium disposal has received growing attention as a potential therapeutic target, since drugs or probiotics that enhance colonic potassium secretion could offer another route for lowering serum levels.15PubMed. The colon: an overlooked site for therapeutics in dialysis patients Whether this intestinal adaptation is enough to make a clinically meaningful difference remains uncertain, and no formal guidelines specify exactly how much dietary restriction is needed at each stage of kidney disease. In practice, blanket potassium restriction may be overly conservative for many people with diabetes and moderately reduced kidney function, particularly if their serum levels are only mildly elevated and stable.
Why All These Mechanisms Stack Up
What makes diabetes such a potent driver of hyperkalemia is that it doesn’t rely on any single pathway. A person with longstanding type 2 diabetes may simultaneously have reduced insulin-mediated cellular uptake of potassium, diminished aldosterone production from low renin, structural kidney damage that impairs tubular secretion, autonomic nerve damage that further blunts renin release, and a medication list that includes an ACE inhibitor and possibly a mineralocorticoid blocker. Each mechanism alone might produce only a modest potassium elevation. Together, they can push serum potassium high enough to affect the heart’s electrical system, where the stakes become life-threatening.
Recognizing this layered nature matters for management. Treating just one of the contributing factors, for instance adjusting a single medication, may not be sufficient if three other mechanisms are still pushing potassium upward. A comprehensive approach that addresses insulin adequacy, medication interactions, kidney function trends, and dietary intake tends to produce better and more durable potassium control than focusing on any single lever. For clinicians, it also means that a new hyperkalemia episode in a person with diabetes warrants a search for what changed: a new medication, worsening kidney function, dietary shifts, or even a lab artifact, rather than assuming the cause is the same one that was identified last time.